Pages
Products
Synapsin-GFP Lentivirus

Synapsin-GFP Lentivirus

Cat.No. :  LV00959Z

Titer: ≥1*10^7 TU/mL / ≥1*10^8 TU/mL / ≥1*10^9 TU/mL Size: 100 ul/500 ul/1 mL

Storage:  -80℃ Shipping:  Frozen on dry ice

Inquire for Price

Lentivirus Particle Information

Quality Control

Cat. No. LV00959Z
Description This lentivirus contains GFP under the control of human synapsin promoter.
Target Gene GFP
Titer Varies lot by lot, for example, ≥1*10^7 TU/mL, ≥1*10^8 TU/mL, ≥1*10^9 TU/mL etc.
Size Varies lot by lot, for example, 100 ul, 500 ul, 1 mL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality lentivirus particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between lentivirus particle lots.
Mycoplasma Creative Biogene routinely tests for mycoplasma contamination using a mycoplasma detection kit. Cell lines are maintained for approximately 20 passages before being discarded and replaced with a new vial of early passage cells. Approximately 2 weeks after thawing, cell culture supernatants are tested for mycoplasma contamination. Creative Biogene ensures that lentiviral products are free of mycoplasma contamination.
Purity Creative Biogene evaluates the level of impurities, such as residual host cell DNA or proteins, in prepared lentiviral vectors to ensure they meet quality standards.
Sterility The lentiviral samples were inoculated into cell culture medium for about 5 days and the growth of bacteria and fungi was tested. Creative Biogene ensures that the lentiviral products are free of microbial contamination.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of lentivirus to deliver genetic material into target cells, and assess gene expression and functional activities.
Proviral Identity Confirmation All Creative Biogene lentiviral vectors are confirmed to have correctly integrated provirus using PCR. This test involves transducing cells with serial dilutions of the lentiviral vector, harvesting the cells a few days later, and isolating genomic DNA. This DNA is then used as a template to amplify a portion of the expected lentiviral insert.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Lentiviral vectors (LVs) carry and express therapeutic genes in the form of independent expression cassettes, which in their simplest form contain an intronless protein coding region (cDNA) transcribed by a promoter and auxiliary regulatory regions and polyadenylated at the viral signal site located in the 3′ long translation terminal (LTR). The desired regulation of transgene expression can be achieved at the transcriptional level by using promoters/enhancers specific to tissues, cell types, or differentiation stages, and/or post-transcriptionally by adding 5′ or 3′ untranslated regions (UTRs) to enhance ribosome binding or mRNA stability, or by adding target sequences for specific microRNAs (miRNAs) to regulate protein expression through physiological RNA interference mechanisms. In addition, viral particle pseudotyping techniques using alternative envelope proteins have been developed to improve transduction of specific cell types, but are rarely used in clinical applications because VSV-G is considered the standard for vector manufacturing. Historically, the first LV vectors were based on the usage of strong viral promoter/enhancer sequences, typically derived from the human CMV or the murine spleen focus forming (SFFV), stem cell (MSCV) or myeloproliferative sarcoma virus (MPSV). However, lentiviruses carrying these promoters have been associated with severe side effects in clinical trials and are no longer used, at least for the transduction of long-lived stem cells. Side effects include insertional mutagenesis due to the long-range cis-enhancing activity of the viral elements on genes flanking the proviral insertion site, or epigenetic silencing due to activation of host cell defense mechanisms. Many preclinical studies have shown that the activity of potent viral promoters/enhancers is the most important factor driving clonal expansion and oncogenicity after lentiviral integration. As a result, viral elements have been replaced by cellular promoters and regulatory sequences in most clinical applications.

Stem cell-derived neurons are typically obtained in bulk culture lacking spatial organization and any meaningful connectivity. Here, researchers implemented a microfluidic system for the long-term culture of human neurons with patterned protrusions and synaptic terminals. Co-culturing human midbrain dopaminergic neurons and striatal medium spiny neurons on a microchip established a coordinated nigrostriatal circuit with functional dopaminergic synapses. The researchers used this platform to dissect mitochondrial dysfunction associated with genetic forms of Parkinson's disease (PD) with OPA1 mutations. Notably, axons of OPA1 mutant dopaminergic neurons exhibited a significant reduction in mitochondrial mass. This defect results in a significant loss of dopaminergic synapses, which is exacerbated by long-term culture. Therefore, the depletion of synaptic mitochondria associated with PD may precede the loss of neuronal connectivity and neurodegeneration. In vitro reconstitution of human circuitries by microfluidic technology offers a powerful system to study brain networks by establishing ordered neuronal compartments and correct synapse identity.

To demonstrate the presence of active monoaminergic synapses, the researchers used the fluorescent probe FFN206, which is a specific and sensitive substrate for VMAT2. FFN206 is taken up by VMAT2-expressing neurons and binds to transporters within acidic synaptic vesicles, maintaining a strong and sustained fluorescence intensity. Five weeks after neurons were seeded into the microdevice, FFN206 was mixed with artificial cerebrospinal fluid (ACSF) buffer and perfused within the central channel (Figure 1A). To specifically identify axonal terminals within the central chamber, the microwells containing DANs were exposed to lentivirus expressing Synapsin-GFP for 24 hours. Lentivirus infection in the microdevice transduced a large number of neurons and maintained them within the microwells without any noticeable diffusion between the microgrooves and other surrounding chambers. KCl-containing medium (56 mM) was perfused into the central channel and the side chambers containing DANs for 10 minutes before starting imaging. Live confocal imaging detected a large number of FFN206+ puncta, most of which colocalized with GFP+ fibers in the central compartment (Figure 1B-1D). It is possible that not all GFP+ fibers could be easily detected at low fluorescence signals in live imaging experiments, thus plausibly explaining why not all FFN206+ puncta could be mapped onto GFP+ axonal branches. These data suggest that a large number of monoaminergic synapses are established in the medial channel and show active recycling of VMAT2+ vesicles in DAT terminals.

Figure 1. DA-Specific Synaptic Identity and Functionality in the Human Nigro-striatal Pathway. (Iannielli A, et al., 2019)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

CBpromise

Our promise to you:
Guaranteed product quality, expert customer support.

24x7 CUSTOMER SERVICE
CONTACT US TO ORDER